AUGMENTED ANTIBODY (Ab) RESPONSES IN INFANTS ADMINISTERED A NEW HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE (PRP) DIPHTHERIA TOXOID CONJUGATE VACCINE (PRP-D)

J. Zahradnik,L. Gordon
DOI: https://doi.org/10.1203/00006450-198404001-01178
IF: 3.953
1984-04-01
Pediatric Research
Abstract:PRP-D, a hapten-carrier conjugate containing 20μg PRP/0.5cc, has previously been shown to be highly immunogenic in adults and young children (<18 mo.) given 2 doses. Ab responses in sera taken 1 mo. post-vac were evaluated in 90 infants administered PRP-D, PRP, or placebo at ages 3, 5 & 7 months. No significant adverse reactions occurred. Anti-PRP responses for the vaccinees shown (Farr assay with SK standard) developed in 14%, 53%,& 100% of PRP-D vaccinees respectively, following the first three doses as compared to 0, 7%, and 60% in PRP vaccinees respectively. A sequential increase in the mean anti-PRP titer was see in the PRP-D group and final mean titers were 5-fold greater than that following PRP:This new PRP-D conjugate vaccine appears to have resulted in an enhanced response since the seroconversion rate and Ab titers were higher than those seen following PRP.
What problem does this paper attempt to address?